Australian Clinical Labs Limited (ASX: ACL) - ETF Exposure

- Current share price for ACL : $2.800

Australian Clinical Labs (ACL) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is an Australian private provider of pathology services. The Company's NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.

ACL General Information ⁺

ASX Code	ACL
Website	http://clinicallabs.com.au
Industry/Sector	Health Care Services
Market Cap ($M)	522
ACL Share Price	$2.800
Day High	$2.830
Day Low	$2.790
Last Close	$2.800
ACL Share Price Movement	- ( No change )

Prices as at 16:40, 8 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to ACL

Australian Clinical Labs Limited (ACL) is held across 19 ETFs spanning strategies that include health care services exposure . Its weighting in those funds means performance can have an outsized influence - when ACL moves, funds like MVS, SSO, ISO, IHD and QOZ that hold it can move with it.

For more concentrated exposure, ETFs such as MVS (VanEck Small Companies Masters ETF) allocate about 1.7% to ACL , while the average exposure across all 19 ETFs that hold it is around 0.1% .

Top ETF holdings

VanEck Small Companies Masters ETF (MVS) ~ 1.7%
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) ~ 0.2%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0.2%
iShares S&P/ASX High Dividend Opportunities ETF (IHD) ~ 0.1%
Betashares FTSE RAFI Australia 200 ETF (QOZ) ~ 0.1%

Last updated: ETF data and holdings as at 8 October 2026

Own ACL directly or through an ETF?

How does holding Australian Clinical Labs Limited (ACL) shares directly compare to ETFs that include it?

	ACL Direct	MVS ASX	SSO ASX	ISO ASX	IHD ASX	QOZ ASX
Holdings	1 company	91 holdings	219 holdings	218 holdings	56 holdings	201 holdings
ACL Weight	100%	1.7%	0.2%	0.2%	0.1%	0.1%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	0.49% p.a.	0.5% p.a.	0.55% p.a.	0.23% p.a.	0.4% p.a.
Approx. Yield	5.8%	2.87%	9.51%	4.48%	5.98%	3.85%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ACL's direct yield. Annual cost uses each ETF's MER.

ACL Exposure on $10,000 investment

How a $10,000 investment in Australian Clinical Labs Limited (ACL) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Australian Clinical Labs Limited (ACL)	Direct share	$2.800	1.45%	+$145	$10,145
VanEck Small Companies Masters ETF (MVS)	Equity - Australia Small/Mid Cap	$20.880	-1.37%	-$137	$9,863
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	Equity - Australia Small/Mid Cap	$14.110	-1.12%	-$112	$9,888
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$4.880	-1.41%	-$141	$9,859
iShares S&P/ASX High Dividend Opportunities ETF (IHD)	Equity - Australia Strategy	$16.310	-1.03%	-$103	$9,897
Betashares FTSE RAFI Australia 200 ETF (QOZ)	Equity - Australia	$19.200	1.37%	+$137	$10,137

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Australian Clinical Labs Limited (ACL) ETFs

19 ETFs hold Australian Clinical Labs Limited (ACL).

ETF	ACL Weight	MER	Yield
VanEck Small Companies Masters ETF (MVS)	1.7%	0.49%	2.87%
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO)	0.2%	0.5%	9.51%
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0.2%	0.55%	4.48%
iShares S&P/ASX High Dividend Opportunities ETF (IHD)	0.1%	0.23%	5.98%
Betashares FTSE RAFI Australia 200 ETF (QOZ)	0.1%	0.4%	3.85%
Dimensional Australian Core Equity (Managed Fund) (DACE)	0.1%	0.28%	3.19%
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0%	0.16%	2.95%
Global X Australia 300 ETF (A300)	0%	0.03%	3.1%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	3.22%
Dimensional Australian Value Trust - Active ETF (DAVA)	0%	0.34%	6.72%

View all 19 ETFs

Australian Clinical Labs Limited (ACL) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
HFResult	9.25¢	100%	2 Sep 2026	23 Sep 2026	-	-	-
Result	3.75¢	100%	12 Mar 2026	31 Mar 2026	-	-	-
HFResult	9¢	100%	1 Sep 2025	23 Sep 2025	-	-	-

See all dividends from Australian Clinical Labs Limited (ACL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Australian Clinical Labs Limited (ACL) price-sensitive announcements

ACL - FY26 financial results investor presentation

Australian Clinical Labs Limited (ACL) reported its FY26 financial results showing a 1.7%

Australian Clinical Labs Limited (ACL)
17 Aug 2026 | 8:08 AM

ACL - Appendix 4E and FY26 financial reports

The document is an Appendix 4E preliminary final report for Australian Clinical Labs Limit

Australian Clinical Labs Limited (ACL)
17 Aug 2026 | 8:08 AM

ACL - Appointment of new Group CEO

Australian Clinical Labs Limited (ACL) announced the appointment of Greg Horan as its new

Australian Clinical Labs Limited (ACL)
28 May 2026 | 9:06 AM

ACL - Class action proceedings

On April 21, 2026, Australian Clinical Labs Limited (ACL) announced that it has been serve

Australian Clinical Labs Limited (ACL)
21 Apr 2026 | 8:14 AM

Australian Clinical Labs Limited (ACL) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	Change of Auditor	2 Oct 2026 3:54PM	$2.790	$2.800	risen by 0.36%
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	Appendix 4G	22 Sep 2026 8:16AM	$2.920	$2.800	fallen by 4.11%
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	2026 Annual Report	22 Sep 2026 8:16AM	$2.920	$2.800	fallen by 4.11%
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	Notice of meeting - 2026 AGM	22 Sep 2026 8:15AM	$2.920	$2.800	fallen by 4.11%
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	Change in substantial holding	18 Sep 2026 4:17PM	$2.880	$2.800	fallen by 2.78%
Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID	Health Care	$522	Change of Director's Interest Notice - S Butler	14 Sep 2026 2:59PM	$2.730	$2.800	risen by 2.56%

ACL Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	DPS	Yield (%)	Franking (%)
2028F	C2	$19.50	4.30%	14.40	12.50	4.50%	0.0%
2027F	C2	$18.70	-1.10%	15.00	13.00	4.60%	0.0%
2026A	$36.67	$18.90	4.40%	12.90	13.00	5.30%	100.0%

ACL Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Australian Clinical Labs Limited (ACL)	$526M	0.0442	-0.0111	0.0428	14.9127	15.0802	14.4615	4.61%	4.61%	4.43%
Integral Diagnostics Limited (IDX)	$800M	0.7037	0.0000	0.1877	16.3985	16.3985	13.8065	4.35%	3.50%	3.97%
Sonic Healthcare Limited (SHL)	$9,307M	0.2969	-0.1774	0.1040	13.6075	16.5422	14.9837	5.74%	5.58%	5.87%

ACL Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.47	14.90	3.49	9.59
Market	0.37	14.00	1.06	0.73
Sector	0.70	21.10	2.12	2.46

ACL Directors

Name	Position	Start Date
Mr Greg John Horan	Chief Executive Officer, Executive Director	31 Aug 2026
Ms Christine Nildra Bartlett	Non-Executive Director	23 Aug 2023
Mr Mark Haberlin	Non-Executive Director	28 Apr 2021
Ms Sarah Butler	Non-Executive Director	1 Feb 2025
Dr Amandeep Kaur Hansra	Non-Executive Director	1 Jul 2026
Mr Stephen Patrick Roche	Non-Executive Director, Non-Executive Chairman	20 Jun 2025

Australian Clinical Labs Limited (ACL) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
10 Sep 2026	BUTLER, Sarah	Buy	Indirect Shares	18,000	$1.000	$18,000.000
19 Feb 2026	BUTLER, Sarah	Buy	Indirect Shares	22,617	$2.210	$49,983.570
28 Oct 2025	ROCHE, Stephen	Buy	Direct Shares	70,000	$2.770	$193,900.000

See all changes in directors' interest & trades for Australian Clinical Labs Limited (ACL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ACL Management

Name	Position
Matthew Cordingley	Chief Financial Officer
Eleanor Padman	Company Secretary

ACL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Australian Clinical Labs Limited (ACL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
29,764,987 (15.16%)	Allan Gray Australia Pty Ltd
14,877,241 (7.58%)	State Street Australia Ltd
14,312,777 (7.29%)	Commonwealth Bank of Australia and its related bodies corporate
14,114,260 (7.19%)	Comet Asia Holdings II Pte Ltd
14,114,260 (7.19%)	Superannuation and Investments HoldCo Pty Ltd and its related bodies
14,007,561 (7.13%)	First Sentier Investors Holdings Pty Limited
14,007,561 (7.13%)	Mitsubishi UFJ Financial Group, Inc.

ACL Calendar of Events

Date	Event
21 September 2027	Report (Annual)
16 August 2027	Report (Prelim)
15 February 2027	Report (Interim)
28 October 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us